loncastuximab tesirine BCL2 Fusion, +2 more biomarkers Diffuse Large B-Cell Lymphoma Relapse/refractory Subsequent line loncastuximab tesirine chemotherapy, +1 more type
rituximab + polatuzumab vedotin + bendamustine BCL2 Fusion, +2 more biomarkers Diffuse Large B-Cell Lymphoma Relapse/refractory Subsequent line bendamustine, +2 more drugs chemotherapy, +2 more types